An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world setting in Japan - Evusheld DBR

Study identifier:D8850R00032

ClinicalTrials.gov identifier:NCT06156982

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world setting in Japan

Medical condition

COVID-19

Phase

N/A

Healthy volunteers

No

Study drug

Evusheld

Sex

All

Actual Enrollment

397

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 06 Dec 2023
Primary Completion Date: 09 Jan 2024
Study Completion Date: 09 Jan 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria